ArticleAnnals of surgical oncology2026
Appendiceal Adenocarcinoma Discovered During Acute Perforated Appendicitis: A Potential Contribution of Prophylactic CRS and HIPEC-A French BIGRENAPE Group Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of peritoneal metastasis (PM) from appendicular adenocarcinoma consists of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). No specific recommendation exists in case of acute appendicular syndrome (AAS) with perforated tumor. PATIENTS AND
methodsData from 12 expert centers from the BIG-RENAPE network were collected. We analyzed 5-year overall survival (OS), 5-year disease-free survival (DFS), and 5-year peritoneal-free survival (PFS) between carcinologic right colectomy (CRC) and prophylactic CRS with HIPEC (pCRS + HIPEC) groups. Survival analysis was also performed between CRC, pCRS + HIPEC, and curative CRS with HIPEC (cCRS + HIPEC) groups.
resultsCarcinologic surgery was performed in 130 patients: 11 in CRC, 44 in pCRS + HIPEC, and 75 in cCRS + HIPEC groups. OS was 96.9% (95% confidence interval [CI]: 91.0-100%) in the pCRS + HIPEC group compared with 51.9% (95% CI 21.6-100%) in the CRC group (p < 0.001). The 5-year DFS was 75.2% (95% CI 60.5-93.5%) in the pCRS + HIPEC group compared with 34.3% (95% CI 11.2-100 %) in the CRC group (p = 0.003). The 5-year PFS was 77.6% (95% CI 63.0-95.6%) in the pCRS + HIPEC group compared with the CRC group 34.3% (95% CI 11.2-100 %) (p = 0.001). When comparing all three groups, OS and DFS were significantly better in the pCRS + HIPEC group compared with the CRC and cCRS + HIPEC groups. There were no significant differences in postoperative morbidity between the three groups.
conclusionsPerforming pCRS + HIPEC in the case of perforated appendiceal adenocarcinoma discovered during AAS seems to be associated with better OS compared with performing CRC. This therapeutic option should systematically be discussed in cases of perforated appendiceal adenocarcinoma discovered during acute appendicitis.
Indexed as
Identifiers
41291359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.